Texas 2021 - 87th Regular

Texas House Bill HCR86 Compare Versions

OldNewDifferences
1-H.C.R. No. 86
1+By: J. Johnson of Harris (Senate Sponsor - Miles) H.C.R. No. 86
2+ (In the Senate - Received from the House May 19, 2021;
3+ May 19, 2021, read first time and referred to Committee on Health &
4+ Human Services; May 21, 2021, reported favorably by the following
5+ vote: Yeas 9, Nays 0; May 21, 2021, sent to printer.)
6+Click here to see the committee vote
27
38
49 HOUSE CONCURRENT RESOLUTION
510 WHEREAS, Sickle cell disease is the most common inherited
611 hemoglobin disorder, but despite its high mortality rates and
712 severe economic impact, the need for effective therapies remains
813 unmet; and
914 WHEREAS, The U.S. Centers for Disease Control and Prevention
1015 estimates that sickle cell disease affects approximately 100,000
1116 Americans, occurring among about 1 in every 365 African American
1217 births and 1 out of every 16,300 Hispanic American births; and
1318 WHEREAS, Sickle cell disease can affect any organ, including
1419 the kidneys, lungs, and spleen; vaso-occlusive crises are common
1520 among patients, causing recurrent episodes of acute pain and
1621 leading to irreversible end-organ damage, poor quality of life, and
1722 stroke; the life expectancy among sufferers is reduced, tragically,
1823 by some 25 to 30 years; and
1924 WHEREAS, According to a 2018 study, sickle cell disease
2025 imposes a nearly $3 billion economic burden on the U.S. healthcare
2126 system each year, of which 57 percent is attributed to hospital
2227 inpatient costs; more than 70 percent of patients are insured under
2328 state Medicaid programs; and
2429 WHEREAS, The sickle cell disease patient community has long
2530 been medically underserved; in 1972, then-president Richard Nixon
2631 signed the Sickle Cell Anemia Control Act and pledged to end neglect
2732 of the disease, but today, patients still encounter social,
2833 economic, cultural, and geographic barriers to quality care,
2934 including inconsistent treatments, high reliance on emergency care
3035 and public health programs, limited participation in clinical
3136 trials, and lack of access to the limited number of medical
3237 providers with appropriate knowledge and experience; and
3338 WHEREAS, With rapid advancement in such technologies as gene
3439 editing, sickle cell disease stakeholders are working diligently to
3540 expand availability of the transformative therapies that are
3641 currently building clinical momentum; in 2018, the National
3742 Institutes of Health launched the National Heart, Lung, and Blood
3843 Institute Cure Sickle Cell Initiative to accelerate the development
3944 of therapies to cure the disease; at the end of the following year,
4045 the Food and Drug Administration granted accelerated approval for a
4146 new treatment, and it has granted Orphan Drug designation to sickle
4247 cell disease therapies in order to encourage scientific innovation;
4348 and
4449 WHEREAS, The costs of sickle cell disease are enormous in
4550 both human and economic terms, but medical science provides hope of
4651 a long-awaited cure; now, therefore, be it
4752 RESOLVED, That the 87th Legislature of the State of Texas
4853 hereby express support for equitable access to transformative
4954 therapies for sickle cell disease.
50- J. Johnson of Harris
51- ______________________________ ______________________________
52- President of the Senate Speaker of the House
53- I certify that H.C.R. No. 86 was adopted by the House on May
54- 18, 2021, by the following vote: Yeas 142, Nays 0, 3 present, not
55- voting.
56- ______________________________
57- Chief Clerk of the House
58- I certify that H.C.R. No. 86 was adopted by the Senate on May
59- 24, 2021, by the following vote: Yeas 30, Nays 0.
60- ______________________________
61- Secretary of the Senate
62- APPROVED: __________________
63- Date
64- __________________
65- Governor
55+ * * * * *